Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
12 Marzo 2024 - 9:00PM
Mdxhealth Adds Hereditary Prostate Cancer
Genetic Test to Prostate Cancer Offering
IRVINE, CA, and HERSTAL,
BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA
(NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage
precision diagnostic company, announces the introduction of a
non-invasive genetic prostate cancer test through its urology sales
channel.
With a simple saliva sample, the new
comprehensive hereditary prostate cancer test offering provides
insights into a patient’s risk of developing cancer, disease
progression, and response to prostate cancer therapies. Germline
testing of prostate cancer patients is recommended in the National
Comprehensive Cancer Network (NCCN) guidelines and is covered by
Medicare and many commercial insurance plans, for eligible
patients.
Michael K. McGarrity, CEO of mdxhealth,
commented: “The addition of this test to our menu reflects
our commitment to delivering clinically actionable precision
diagnostics to our urology customer base, providing both clinicians
and patients with insights into the diagnosis and treatment of
prostate cancer, particularly where genetic factors play a critical
role. Given the established clinical guidelines and reimbursement,
we believe this portfolio addition will contribute to revenue and
growth in the second half of this year.”
Prostate cancer remains a leading cause of
cancer-related death among men, with an estimated 288,300 new
diagnoses and 34,700 deaths annually. Decades of research indicate
that prostate cancer has a strong genetic component with
implications to ancestry.
About mdxhealth
Mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. For more information, visit mdxhealth.com and follow us
on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth
and linkedin.com/company/mdxhealth.
For more information:
info@mdxhealth.com
LifeSci Advisors (IR &
PR)US: +1 949 271 9223ir@mdxhealth.com
This press release contains forward-looking
statements and estimates with respect to the anticipated future
performance of MDxHealth and the market in which it operates, all
of which involve certain risks and uncertainties. These statements
are often, but are not always, made through the use of words or
phrases such as “potential,” “expect,” “will,” “goal,” “next,”
“potential,” “aim,” “explore,” “forward,” “future,” and “believes”
as well as similar expressions. Forward-looking statements
contained in this release include, but are not limited to,
statements regarding expected future operating results;
expectations for development of new or improved products and
services and their impact on patients; our strategies, positioning,
resources, capabilities and expectations for future events or
performance; and the anticipated benefits of our acquisitions,
including estimated synergies and other financial impacts. Such
statements and estimates are based on assumptions and assessments
of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual
events are difficult to predict, may depend upon factors that are
beyond the company’s control, and may turn out to be materially
different. Examples of forward-looking statements include, among
others, statements we make regarding expected future operating
results, product development efforts, our strategies, positioning,
resources, capabilities and expectations for future events or
performance. Important factors that could cause actual results,
conditions and events to differ materially from those indicated in
the forward-looking statements include, among others, the
following: our ability to successfully and profitably market our
products; the acceptance of our products and services by healthcare
providers; our ability to achieve and maintain adequate levels of
coverage or reimbursement for our current and future solutions we
commercialize or may seek to commercialize; the willingness of
health insurance companies and other payers to cover our products
and services and adequately reimburse us for such products and
services; our ability to obtain and maintain regulatory approvals
and comply with applicable regulations; timing, progress and
results of our research and development programs; the period over
which we estimate our existing cash will be sufficient to fund our
future operating expenses and capital expenditure requirements; the
possibility that the anticipated benefits from our business
acquisitions like our acquisition of the Oncotype DX® GPS prostate
cancer business will not be realized in full or at all or may take
longer to realize than expected; and the amount and nature of
competition for our products and services. Other important risks
and uncertainties are described in the Risk Factors sections of our
most recent Annual Report on Form 20-F and in our other reports
filed with the Securities and Exchange Commission. MDxHealth
expressly disclaims any obligation to update any such
forward-looking statements in this release to reflect any change in
its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based
unless required by law or regulation. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of MDxHealth in any jurisdiction. No
securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws.
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. The GPS test was formerly known as and is
frequently referenced in guidelines, coverage policies,
reimbursement decisions, manuscripts and other literature as
Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate
Score, and Oncotype Dx Prostate Cancer Assay, among others. The
Oncotype DX trademark, and all other trademarks and service marks,
are the property of their respective owners.
Grafico Azioni MDxHealth (NASDAQ:MDXH)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni MDxHealth (NASDAQ:MDXH)
Storico
Da Nov 2023 a Nov 2024
